[go: up one dir, main page]

NO20092149L - Spiro-piperidinderivater - Google Patents

Spiro-piperidinderivater

Info

Publication number
NO20092149L
NO20092149L NO20092149A NO20092149A NO20092149L NO 20092149 L NO20092149 L NO 20092149L NO 20092149 A NO20092149 A NO 20092149A NO 20092149 A NO20092149 A NO 20092149A NO 20092149 L NO20092149 L NO 20092149L
Authority
NO
Norway
Prior art keywords
spiro
piperidine
present
compounds
anxiety
Prior art date
Application number
NO20092149A
Other languages
English (en)
Inventor
Patrick Schnider
Hasane Ratni
Christophe Grundschober
Mark Rogers-Evans
Rafaello Masciadri
Caterina Bissantz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20092149L publication Critical patent/NO20092149L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår nye spiro-piperidin-derivater som V1a reseptorantagonister, fremstilling av dem, farmasøytiske preparater inneholdende dem og anvendelse av dem som medikamenter. De aktive forbindelser ifølge foreliggende oppfinnelse er anvendelige ved forebygging og/eller behandling av angst og depressive lidelser og andre sykdommer. Forbindelsene ifølge oppfinnelsen er beskrevet med den generelle formel (I) (I) hvor R1 til R5, R5', R7 til R9, R7', R8', X og Y er som definert i beskrivelsen.
NO20092149A 2006-12-22 2009-06-03 Spiro-piperidinderivater NO20092149L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06127086 2006-12-22
PCT/EP2007/063879 WO2008077810A2 (en) 2006-12-22 2007-12-13 Spiro-piperidine derivatives

Publications (1)

Publication Number Publication Date
NO20092149L true NO20092149L (no) 2009-06-18

Family

ID=39209551

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092149A NO20092149L (no) 2006-12-22 2009-06-03 Spiro-piperidinderivater

Country Status (16)

Country Link
US (3) US8084609B2 (no)
EP (2) EP2535329A3 (no)
JP (1) JP2010513384A (no)
KR (1) KR20090082502A (no)
CN (1) CN101563324A (no)
AR (1) AR064481A1 (no)
AU (1) AU2007338115A1 (no)
BR (1) BRPI0721138A2 (no)
CA (1) CA2673307A1 (no)
CL (1) CL2007003720A1 (no)
MX (1) MX2009006454A (no)
NO (1) NO20092149L (no)
PE (1) PE20081833A1 (no)
RU (1) RU2009123133A (no)
TW (1) TW200833697A (no)
WO (1) WO2008077810A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720004A2 (pt) * 2006-12-07 2013-12-17 Hoffmann La Roche Derivados de espiro-piperidina como antagonista de receptor v1a
EP2535329A3 (en) * 2006-12-22 2013-03-27 F. Hoffmann-La Roche AG Spiro-piperidine derivatives
US8710046B2 (en) 2009-07-14 2014-04-29 Albany Molecular Research, Inc. 5-HT3 receptor modulators, methods of making, and use thereof
JP6196302B2 (ja) 2012-07-10 2017-09-13 バイエル・ファルマ・アクティエンゲゼルシャフト ３−置換エストラ−１，３，５（１０），１６−テトラエン誘導体、その調製法、これらを含む医薬製剤および医薬を調製するためのその使用
SG11201505875WA (en) 2013-02-21 2015-09-29 Bayer Pharma AG Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3)
TWI848031B (zh) 2018-12-17 2024-07-11 美商維泰克斯製藥公司 Apol1抑制劑及其使用方法
CR20230132A (es) 2020-08-26 2023-06-27 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
CA3251155A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Spiropiperidine derivatives used as APOL1 inhibitors and their methods of use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3370091A (en) * 1964-06-15 1968-02-20 Hoffmann La Roche 2 aminobenzhydrylhalides
US3531467A (en) * 1966-12-23 1970-09-29 Hoffmann La Roche Process for the preparation of 2,3,4,5-tetrahydro - 5 - aryl - 1h - 1,4 - benzodiazepine derivatives
US4209625A (en) * 1977-04-21 1980-06-24 American Hoechst Corporation Spiro[indoline-3,4'-piperidine]s
DE3818830A1 (de) * 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
DK78692D0 (da) 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
EP0663827A4 (en) * 1992-10-07 1995-11-15 Merck & Co Inc TOKOLYTIC OXYTOCINE RECEPTOR ANTAGONISTS.
US5670509A (en) * 1993-09-27 1997-09-23 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
IT1271026B (it) 1994-10-21 1997-05-26 Isagro Ricerca Srl Derivati dell'acido b-amminopropionico ad attivita' fungicida
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
DE69620241T2 (de) * 1995-12-14 2002-10-02 MERCK & CO., INC. (A NEW JERSEY CORP.) Gonadotropin releasing hormon- antagonisten
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
CO5150201A1 (es) 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
CA2348234A1 (en) 1998-10-29 2000-05-11 Chunjian Liu Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
GB0003397D0 (en) * 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
CA2405971C (en) 2000-05-12 2010-03-30 Solvay Pharmaceuticals B.V. New piperazine and piperidine compounds
AU2001292579A1 (en) 2000-09-29 2002-04-15 Eli Lilly And Company Methods and compounds for treating proliferative diseases
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
ATE391505T1 (de) 2001-11-27 2008-04-15 Hoffmann La Roche Benzothiazole derivative
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
US20040152741A1 (en) 2002-09-09 2004-08-05 Nps Allelix Corporation Arylglycine derivatives and their use as glycine transport inhibitors
AU2003263155A1 (en) 2002-09-20 2004-04-08 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
PL377215A1 (pl) 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
AU2003215549A1 (en) 2003-02-03 2004-08-30 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7244852B2 (en) * 2003-02-27 2007-07-17 Abbott Laboratories Process for preparing 2-methylpyrrolidine and specific enantiomers thereof
JP2006522125A (ja) 2003-03-25 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
US20050113398A1 (en) 2003-08-07 2005-05-26 Ankush Argade 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
CA2544602A1 (en) 2003-11-04 2005-05-26 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US20070254903A1 (en) 2003-12-23 2007-11-01 Arena Pharmaceuticals, Inc. Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof
JP4787254B2 (ja) 2004-08-05 2011-10-05 エフ．ホフマン−ラ ロシュ アーゲー インドール、インダゾールまたはインドリン誘導体
WO2006040329A1 (en) 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
US20080234252A1 (en) * 2005-05-18 2008-09-25 Pfizer Inc Compounds Useful in Therapy
US8190027B2 (en) * 2006-07-12 2012-05-29 Tellabs Operations, Inc. Multifunctional and reconfigurable optical node and optical network
RU2414466C2 (ru) * 2005-07-14 2011-03-20 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ИНДОЛ-3-КАРБОНИЛ-СПИРО-ПИПЕРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ V1a
WO2007028638A1 (en) * 2005-09-09 2007-03-15 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
KR101467723B1 (ko) 2005-11-01 2014-12-03 탈자진 인코포레이티드 키나제의 비-아릴 메타-피리미딘 억제제
US20100105904A1 (en) 2006-05-19 2010-04-29 Teiji Kimura Urea type cinnamide derivative
US20080027001A1 (en) 2006-07-07 2008-01-31 Andrew Wood Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
BRPI0720004A2 (pt) 2006-12-07 2013-12-17 Hoffmann La Roche Derivados de espiro-piperidina como antagonista de receptor v1a
EP2535329A3 (en) * 2006-12-22 2013-03-27 F. Hoffmann-La Roche AG Spiro-piperidine derivatives
CA2674154A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Azaspiro derivatives
ES2376378T3 (es) * 2007-01-12 2012-03-13 F. Hoffmann-La Roche Ag Derivados de espiropiperidina-glicinamida.
MX2009012163A (es) 2007-05-11 2009-12-01 Hoffmann La Roche Hetarilanilinas como moduladores para beta-amiloide.
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors

Also Published As

Publication number Publication date
EP2535329A2 (en) 2012-12-19
BRPI0721138A2 (pt) 2014-04-01
CL2007003720A1 (es) 2008-07-11
PE20081833A1 (es) 2008-12-27
CA2673307A1 (en) 2008-07-03
CN101563324A (zh) 2009-10-21
MX2009006454A (es) 2009-06-26
US20080153863A1 (en) 2008-06-26
JP2010513384A (ja) 2010-04-30
US20080153861A1 (en) 2008-06-26
US8084609B2 (en) 2011-12-27
AR064481A1 (es) 2009-04-01
AU2007338115A1 (en) 2008-07-03
WO2008077810A3 (en) 2008-09-25
EP2535329A3 (en) 2013-03-27
EP2097376A2 (en) 2009-09-09
TW200833697A (en) 2008-08-16
RU2009123133A (ru) 2011-01-27
WO2008077810A2 (en) 2008-07-03
KR20090082502A (ko) 2009-07-30
US20080153862A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
NO20092342L (no) Azaspiroderivativater
NO20091766L (no) Spiro-piperidinderivater
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20092149L (no) Spiro-piperidinderivater
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
NO20090328L (no) Nye forbindelser 385
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20073719L (no) Kjemiske forbindelser
NO20090760L (no) Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet
NO20090327L (no) Nye forbindelser 384
NO20082709L (no) Kjemiske forbindelser
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
NO20085100L (no) Nye forbindelser
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application